Ads
related to: biib
Search results
Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
Zacks via Yahoo Finance· 5 hours agoThis Score can pinpoint good times to build a position in a stock, using factors like one-week price...
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Zacks via Yahoo Finance· 6 days agoBiogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA...
Ionis, Biogen Down on Ending Development of ALS Drug - Biogen (NASDAQ:BIIB), Heron Therapeutics...
Benzinga· 4 days agoShares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market...
Biogen and Ionis halt ALS drug development after trial setback By Investing.com
Investing.com· 5 days agoBiogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have announced the...
Avadel Pharmaceuticals appoints new board member By Investing.com
Investing.com· 2 hours agoAvadel Pharmaceuticals plc (NASDAQ:AVDL), a company specializing in developing innovative...
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic...
Morningstar· 5 days agoBiogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense ...
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
Market Watch· 5 days ago“However, over the 6-month placebo-controlled period, treatment with BIIB105 did not result in a...
Press Releases
Morning Times· 6 days ago(Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") ...
Biogen, Ionis to discontinue development of ALS drug
Reuters· 5 days ago, opens new tab said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after...
...Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast...
Benzinga· 7 days agoTOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:
